E081 Effectiveness of intravenous belimumab in patients with systemic lupus erythematosus at a UK tertiary referral centre
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.330
Abstract: Belimumab was approved in the United Kingdom (UK) in 2016 as add-on therapy for patients with auto-antibody positive systemic lupus erythematosus (SLE) and high disease activity refractory to standard treatment. Data regarding the effectiveness of… read more here.
Keywords: belimumab; selena sledai; systemic lupus; lupus erythematosus ... See more keywords
Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial
Sign Up to like & getrecommendations! Published in 2019 at "Lupus"
DOI: 10.1177/0961203319886065
Abstract: Objectives To quantify changes in generic patient-reported outcomes against clinically meaningful, disease activity measures in systemic lupus erythematosus (SLE). Methods Using BLISS-52 trial data (867 SLE patients), we estimated the mean difference in change of… read more here.
Keywords: index; disease; selena sledai; disease activity ... See more keywords
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Sign Up to like & getrecommendations! Published in 2025 at "Lupus"
DOI: 10.1177/09612033251337130
Abstract: Objective To investigate the effects of belimumab (BEL) on systemic lupus erythematosus (SLE) mucocutaneous and vasculitis manifestations. Methods This post hoc, integrated Belimumab Summary of Lupus Efficacy (Be-SLE) analysis pooled data from five international Phase… read more here.
Keywords: selena sledai; vasculitis; bel; mucocutaneous vasculitis ... See more keywords